242 related articles for article (PubMed ID: 9674399)
21. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti CM; LeMaistre CF
Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.
Duvic M; Martin AG; Olsen EA; Fivenson DP; Prince HM
Leuk Lymphoma; 2013 Mar; 54(3):514-9. PubMed ID: 22891708
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
[TBL] [Abstract][Full Text] [Related]
24. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
25. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.
Duvic M; Geskin L; Prince HM
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):377-84. PubMed ID: 23770157
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
Frankel AE; Zuckero SL; Mankin AA; Grable M; Mitchell K; Lee YJ; Neville DM; Woo JH
Curr Drug Targets; 2009 Feb; 10(2):104-9. PubMed ID: 19199905
[TBL] [Abstract][Full Text] [Related]
28. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
29. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial.
Bagel J; Garland WT; Breneman D; Holick M; Littlejohn TW; Crosby D; Faust H; Fivenson D; Nichols J
J Am Acad Dermatol; 1998 Jun; 38(6 Pt 1):938-44. PubMed ID: 9632001
[TBL] [Abstract][Full Text] [Related]
30. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
[TBL] [Abstract][Full Text] [Related]
31. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
Talpur R; Apisarnthanarax N; Ward S; Duvic M
Leuk Lymphoma; 2002 Jan; 43(1):121-6. PubMed ID: 11908715
[TBL] [Abstract][Full Text] [Related]
32. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.
Ohmachi K; Ando K; Ogura M; Uchida T; Tobinai K; Maruyama D; Namiki M; Nakanishi T
Cancer Sci; 2018 Mar; 109(3):794-802. PubMed ID: 29363235
[TBL] [Abstract][Full Text] [Related]
33. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma.
Hesketh P; Caguioa P; Koh H; Dewey H; Facada A; McCaffrey R; Parker K; Nylen P; Woodworth T
J Clin Oncol; 1993 Sep; 11(9):1682-90. PubMed ID: 8355035
[TBL] [Abstract][Full Text] [Related]
34. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
[No Abstract] [Full Text] [Related]
35. Treatment of cutaneous T-cell lymphoma/mycosis fungoides.
Parker SR; Bradley B
Dermatol Nurs; 2006 Dec; 18(6):566-70, 573-5. PubMed ID: 17286158
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
[TBL] [Abstract][Full Text] [Related]
37. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma.
Duvic M; Cather J; Maize J; Frankel AE
Am J Hematol; 1998 May; 58(1):87-90. PubMed ID: 9590158
[TBL] [Abstract][Full Text] [Related]
38. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
39. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
40. New advances in the management of cutaneous T-cell lymphoma.
Young SK
Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
